Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Plaza-Menacho

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Endocrine-Related Cancer|January 20, 2018
Novel targeted therapeutics for MEN2Sara Redaelli, Ivan Plaza-Menacho, Luca Mologni
Trends in Molecular Medicine|January 22, 2011
RET in breast cancer: functional and therapeutic implicationsAndrea Morandi, Ivan Plaza-Menacho, Clare M Isacke
Molecular and Cellular Endocrinology|July 2, 2013
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinaseLuca Mologni, Sara Redaelli, Andrea Morandi, et al.
Science Advances|September 22, 2016
Cyclic di-GMP mediates a histidine kinase/phosphatase switch by noncovalent domain cross-linkingBadri N Dubey, Christian Lori, Shogo Ozaki, et al.
Trends in Genetics : TIG|September 19, 2006
Current concepts in RET-related genetics, signaling and therapeuticsIvan Plaza-Menacho, Grzegorz M Burzynski, Jan Willem de Groot, et al.
Cancer Research|December 20, 2007
A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancerSelma Esseghir, S Katrina Todd, Toby Hunt, et al.
Cancer Research|May 8, 2013
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitorsAndrea Morandi, Lesley-Ann Martin, Qiong Gao, et al.
European Journal of Human Genetics : EJHG|May 13, 2004
Localizing a putative mutation as the major contributor to the development of sporadic Hirschsprung disease to the RET genomic sequence between the promoter region and exon 2Grzegorz M Burzynski, Ilja M Nolte, Jan Osinga, et al.
American Journal of Human Genetics|March 11, 2005
Identifying candidate Hirschsprung disease-associated RET variantsGrzegorz M Burzynski, Ilja M Nolte, Agnes Bronda, et al.
Cancer Research|March 9, 2005
RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factorIvan Plaza Menacho, Roelof Koster, Almer M van der Sloot, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Endocrine-Related Cancer|January 20, 2018
Novel targeted therapeutics for MEN2Sara Redaelli, Ivan Plaza-Menacho, Luca Mologni
Trends in Molecular Medicine|January 22, 2011
RET in breast cancer: functional and therapeutic implicationsAndrea Morandi, Ivan Plaza-Menacho, Clare M Isacke
Molecular and Cellular Endocrinology|July 2, 2013
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinaseLuca Mologni, Sara Redaelli, Andrea Morandi, et al.
Science Advances|September 22, 2016
Cyclic di-GMP mediates a histidine kinase/phosphatase switch by noncovalent domain cross-linkingBadri N Dubey, Christian Lori, Shogo Ozaki, et al.
Trends in Genetics : TIG|September 19, 2006
Current concepts in RET-related genetics, signaling and therapeuticsIvan Plaza-Menacho, Grzegorz M Burzynski, Jan Willem de Groot, et al.
Cancer Research|December 20, 2007
A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancerSelma Esseghir, S Katrina Todd, Toby Hunt, et al.
Cancer Research|May 8, 2013
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitorsAndrea Morandi, Lesley-Ann Martin, Qiong Gao, et al.
European Journal of Human Genetics : EJHG|May 13, 2004
Localizing a putative mutation as the major contributor to the development of sporadic Hirschsprung disease to the RET genomic sequence between the promoter region and exon 2Grzegorz M Burzynski, Ilja M Nolte, Jan Osinga, et al.
American Journal of Human Genetics|March 11, 2005
Identifying candidate Hirschsprung disease-associated RET variantsGrzegorz M Burzynski, Ilja M Nolte, Agnes Bronda, et al.
Cancer Research|March 9, 2005
RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factorIvan Plaza Menacho, Roelof Koster, Almer M van der Sloot, et al.
Pageof 1